More Questions About Aspartame

WebMD reports an Italian study of rats links low doses of aspartame -- the sweetener in NutraSweet, Equal, and thousands of consumer products -- to leukemia and lymphoma. But food industry officials point out that many other studies have found no link between aspartame and cancer.



The rats in the study were fed various doses of aspartame throughout their lives. In female but not male rats, lymphoma and leukemia were significantly associated with daily aspartame doses as low as 20 milligrams (mg) per kilogram (kg) of body weight. To reach a dose of 20 mg/kg, a 140-pound woman would need to drink three cans of diet soda a day. A 180-pound man would need to drink four cans of diet soda a day. The sweetener is also in thousands of products, ranging from yogurt to over-the-counter medicines.



The average person consumes about 2 or 3 mg/kg aspartame each day. However, that figure goes way up for children and young women. The study comes from a research team led by Morando Soffritti, MD, scientific director of the European Ramazzini Foundation of Oncology and Environmental Sciences in Bologna, Italy.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap